Understanding SCP2: Potential Drug Target and Biomarker for Diseases

Target Name: SCP2

NCBI ID: G6342

SCP2

Understanding SCP2: Potential Drug Target and Biomarker for Diseases

SCP2, also known as Straight-chain acyl-CoA oxidase, is a protein that is expressed in various tissues throughout the body. It plays a crucial role in the metabolism of fatty acids, breaking down the double bonds in fatty acids to produce energy.

Research has shown that SCP2 is a potential drug target and may be used as a biomarker for certain diseases. In this article, we will explore the biology and potential therapeutic applications of SCP2.

The Structure and Function of SCP2

SCP2 is a member of the acyl-CoA oxidase family, which is a group of enzymes that are involved in the metabolism of fatty acids. These enzymes belong to the superfamily of CoA-oxidases and are characterized by the presence of a single active site and a long extensible catalytic arm.

The catalytic arm of SCP2 consists of a Rossmann-fold, a core heme protein, and a carboxy-subunits. The Rossmann-fold is a structural motif that is found in proteins that are involved in the catalytic cycles of various enzymes, including the acyl -CoA oxidase family. The carboxy-subunit contains a zinc ion, which is involved in the catalytic mechanism.

SCP2 is expressed in various tissues throughout the body, including muscle, heart, brain, and liver. It is also highly expressed in the liver, which is the primary site of its synthesis. The liver-expressed form of SCP2 is a 12-kDa protein, while the brain-expressed form is a 20-kDa protein.

Potential Therapeutic Applications of SCP2

SCP2 has been identified as a potential drug target due to its involvement in the metabolism of fatty acids. Many diseases are caused by the dysfunction of fatty acid metabolism, including obesity, non-alcoholic fatty liver disease, and cardiovascular disease.

One of the potential therapeutic applications of SCP2 is as a treatment for obesity. Obesity is a complex disease that is caused by the combination of genetic, environmental, and behavioral factors. SCP2 has been shown to regulate the metabolism of fatty acids, which may be a potential target for interventions aimed at reducing obesity.

Another therapeutic potential application of SCP2 is as a treatment for non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition that is characterized by the accumulation of fat in the liver, which can lead to the development of various diseases, including liver cirrhosis and non-alcoholic steatohepatitis.

SCP2 has also been shown to be involved in the regulation of cellular signaling pathways, including the production of reactive oxygen species (ROS). ROS are highly reactive molecules that can damage cellular components and contribute to a variety of diseases, including cancer and neurodegenerative diseases.

In addition to its potential therapeutic applications, SCP2 has also been identified as a potential biomarker for certain diseases. The liver-expressed form of SCP2 has been shown to be highly predictive of the outcome of patients with NAFLD, a condition that is characterized by the accumulation of fat in the liver.

Conclusion

In conclusion, SCP2 is a protein that is expressed in various tissues throughout the body and plays a crucial role in the metabolism of fatty acids. Research has shown that SCP2 is a potential drug target and may be used as a biomarker for certain diseases. Its potential therapeutic applications include the treatment of obesity and NAFLD, as well as the regulation of cellular signaling pathways. Further research is needed to fully understand the role of SCP2 in the biology of the body and its potential as a therapeutic agent.

Protein Name: Sterol Carrier Protein 2

Functions: Plays a crucial role in the peroxisomal oxidation of branched-chain fatty acids (PubMed:10706581). Catalyzes the last step of the peroxisomal beta-oxidation of branched chain fatty acids and the side chain of the bile acid intermediates di- and trihydroxycoprostanic acids (DHCA and THCA) (PubMed:10706581). Also active with medium and long straight chain 3-oxoacyl-CoAs. Stimulates the microsomal conversion of 7-dehydrocholesterol to cholesterol and transfers phosphatidylcholine and 7-dehydrocholesterol between membrances, in vitro (By similarity). Isoforms SCP2 and SCPx cooperate in peroxisomal oxidation of certain naturally occurring tetramethyl-branched fatty acyl-CoAs (By similarity)

The "SCP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets